Abstract
Objective To assess the prevalence of impaired health status and physical and mental health symptoms among individuals at least six months after SARS-CoV-2 infection, and to characterise their healthcare utilisation.
Design Population-based prospective cohort study.
Setting Zurich SARS-CoV-2 Cohort, Zurich, Switzerland.
Participants 431 adults from the general population with PCR-confirmed SARS-CoV-2 infection reported to health authorities between 27 February 2020 and 05 August 2020.
Main outcome measures We assessed the proportion of individuals reporting not having fully recovered since SARS-CoV-2 infection, the proportion reporting fatigue (assessed by Fatigue Assessment Scale), dyspnoea (assessed by mMRC dyspnoea scale) or depression (assessed by DASS-21) at six to eight months after diagnosis. We further evaluated the proportion of individuals with at least one healthcare contact since their acute illness. Multivariable logistic regression models were used to assess factors associated with the main outcomes.
Results Symptoms were present in 385 (89%) participants at diagnosis and 81 (19%) were initially hospitalised. At six to eight months, 111 (26%) reported not having fully recovered. 233 (55%) participants reported symptoms of fatigue, 96 (25%) had at least grade 1 dyspnoea, and 111 (26%) had DASS-21 scores indicating symptoms of depression. 170 (40%) participants reported at least one general practitioner visit related to COVID-19 after acute illness, and 10% (8/81) of initially hospitalised individuals were rehospitalised. Individuals that have not fully recovered or suffer from fatigue, dyspnoea or depression were more likely to have further healthcare contacts. However, a third of individuals (37/111) that have not fully recovered did not seek further care.
Conclusion In our population-based study, a relevant proportion of individuals suffered from longer-term consequences after SARS-CoV-2 infection. Our findings indicate that a considerable number of individuals affected by post-COVID-19 syndrome is to be expected, and that a wide range of additional healthcare services and integrative approaches will be required to support the recovery of these individuals. Thus, the timely planning of resources and services for post-COVID-19 care will be necessary alongside public health measures to mitigate the effects of the pandemic.
Registration ISRCTN14990068
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
ISRCTN14990068
Funding Statement
The Zurich SARS-CoV-2 Cohort study is part of the Corona Immunitas research program, coordinated by the Swiss School of Public Health (SSPH+) and funded through SSPH+ fundraising, including funding by the Swiss Federal Office of Public Health, the Cantons of Switzerland (Basel, Vaud and Zurich), private funders (ethical guidelines for funding stated by SSPH+ were respected) and institutional funds of the participating universities. Additional funding specific to this study was provided by the Cantonal Health Directorate Zurich and the University of Zurich Foundation. Study funders had no role in the study design, data collection, analysis, interpretation, or writing of this report.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the responsible ethics committee of the Canton of Zurich, Switzerland (Kantonale Ethik-Kommission Zürich; BASEC-Nr. 2020-01739).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
We are open to sharing de-identified individual participant data that underlie the results reported in this article. Requests can be made to the corresponding author. Data requestors will need to sign a data access agreement.
